BOTULINUM NEUROTOXIN A IMMUNE FAB2 / BOTULINUM NEUROTOXIN B IMMUNE FAB2 / BOTULINUM NEUROTOXIN C IMMUNE FAB2 / BOTULINUM NEUROTOXIN D IMMUNE FAB2 / BOTULINUM NEUROTOXIN E IMMUNE FAB2 / BOTULINUM NEUROTOXIN F IMMUNE FAB2 / BOTULINUM NEUROTOXIN G IMMUNE FAB2 Injection
- Category(s)
- other
- SPL Type(s)
- Plasma Derivative
- Master SPL
- Cangene Corporation (2015-09-01)
- Oldest Current Product
- 2013-03-01
- License(s)
- BLA
- RxNORM
- INJECTION\BOTULINUM NEUROTOXIN A IMMUNE FAB2:BOTULINUM NEUROTOXIN B IMMUNE FAB2:BOTULINUM NEUROTOXIN C IMMUNE FAB2:BOTULINUM NEUROTOXIN D IMMUNE FAB2:BOTULINUM NEUROTOXIN E IMMUNE FAB2:BOTULINUM NEUROTOXIN F IMMUNE FAB2:BOTULINUM NEUROTOXIN G IMMUNE FAB2
- SPL Active
- INTRAVENOUS\LIQUID\EQUINE BOTULINUM NEUROTOXIN A IMMUNE FAB2: EQUINE BOTULINUM NEUROTOXIN B IMMUNE FAB2: EQUINE BOTULINUM NEUROTOXIN C IMMUNE FAB2: EQUINE BOTULINUM NEUROTOXIN D IMMUNE FAB2: EQUINE BOTULINUM NEUROTOXIN E IMMUNE FAB2: EQUINE BOTULINUM NEUROTOXIN F IMMUNE FAB2: EQUINE BOTULINUM NEUROTOXIN G IMMUNE FAB2
- SPL Moiety
- INTRAVENOUS\LIQUID\EQUINE BOTULINUM NEUROTOXIN A IMMUNE FAB2: EQUINE BOTULINUM NEUROTOXIN B IMMUNE FAB2: EQUINE BOTULINUM NEUROTOXIN C IMMUNE FAB2: EQUINE BOTULINUM NEUROTOXIN D IMMUNE FAB2: EQUINE BOTULINUM NEUROTOXIN E IMMUNE FAB2: EQUINE BOTULINUM NEUROTOXIN F IMMUNE FAB2: EQUINE BOTULINUM NEUROTOXIN G IMMUNE FAB2
product(s) by strength(s)
botulinum neurotoxin a immune fab2, equine 4500 unt / botulinum neurotoxin b immune fab2, equine 3300 unt / botulinum neurotoxin c immune fab2, equine 3000 unt / botulinum neurotoxin d immune fab2, equine 600 unt / botulinum neurotoxin e immune fab2, equine 5100 unt / botulinum neurotoxin f immune fab2, equine 3000 unt / botulinum neurotoxin g immune fab2, equine 600 unt injection
original product(s)(s)
| # | id | category | labeler | first marketed | active ingredient(s) | route | dose form | application | spl |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 604920075 | BLA | Cangene Corporation | 2013-03-01 | EQUINE BOTULINUM NEUROTOXIN A IMMUNE FAB2, EQUINE BOTULINUM NEUROTOXIN B IMMUNE FAB2, EQUINE BOTULINUM NEUROTOXIN C IMMUNE FAB2, EQUINE BOTULINUM NEUROTOXIN D IMMUNE FAB2, EQUINE BOTULINUM NEUROTOXIN E IMMUNE FAB2, EQUINE BOTULINUM NEUROTOXIN F IMMUNE FAB2, EQUINE BOTULINUM NEUROTOXIN G IMMUNE FAB2 | INTRAVENOUS | LIQUID | 125462 | 9f3c4292-8773-4781-8264-d71c80d3eabd |
application(s)
| # | id | title | approved | tradenames | fda division |
|---|---|---|---|---|---|
| 1 | 125462 | Botulism Antitoxin Heptavalent (A B C D E F G) - (Equine) Application | 2013-03-22 | BAT | CBER |
spl(s)
| # | id | title | category | type | labeler | labeler act | last update | version | product(s) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 9f3c4292-8773-4781-8264-d71c80d3eabd (view SPL) | These highlights do not include all the information needed to use BAT safely and effectively. See full prescribing information for BAT.BAT, [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)]Sterile Solution for InjectionInitial U.S. Approval: 2013 | other | Plasma Derivative | Cangene Corporation | MANUFACTURE | 2015-09-01 | 1 | 604920075 |
Data from: FDAOB, FDAPB, LOINC, MTHSPL, NDFRT, NCIT, RxNORM, UNII